Xue-Feng Bai, MD, PhD is a Professor in the Experimental Pathology Branch. He earned his MD from the Third Medical University of PLA, Chongqqing China and his PhD at the Karolinska Institute in Stockholm, Sweden. He completed one year of postdoctoral training in the Division of Immunology, Department of Pathology at New York University Medical Center in New York City and two years of postdoctoral training in the Department of Pathology at The Ohio State University Medical Center. Dr. Bai’s research focuses on T cell responses in autoimmune diseases and cancer immunotherapy.
- Title: CD200R signaling in tumor growth, immunity and immunotherapy
- Role: PI
- Goals: To determine the role of CD200R signaling in regulating tumor microenvironment, and its subsequent role in tumor growth, immunity and immunotherapy.
- Sponsor: R01 CA211014-01A1 (NIH/NCI)
- Dates: 08/01/2018 - 07/31/2023
- Title: IL-27 as a potential immunotherapeutic for cancer
- Role: PI
- Goals: To evaluate if AAV-IL-27 can be used as a potential immunotherapeutic in cancer models, and determine the potential mechanisms of action.
- Sponsor: R01CA229254-01A1 (NIH/NCI)
- Dates: 07/01/2019 - 06/30/2024
Academic and Medical Appointments
2019 - presentProfessor, Department of Pathology, The Ohio State University
2010 - 2019 Associate Professor, Department of Pathology, The Ohio State University
2005 - present Graduate Faculty (PhD Adviser), The Ohio State University College of Medicine, Integrated Biomedical Science Graduate Program (IBGP)
2003 - present Member, The Ohio State University Comprehensive Cancer Center, James Cancer Hospital & Solove Research Institute. Columbus, OH
Education and Training
1998 - 2000 Postdoctoral Associate, Immunology, The Ohio State University Department of Pathology, Columbus, OH
1998 Ph.D., Karolinska Institute, Stockholm, Sweden
1988 - 1990 Resident, Internal medicine, Third Military Medical University, Chongqing, China.
1988 M.D., Third Military Medical University, Chongqing, China